The FDA said in the letter that the video "greatly misrepresent[ed]" the drug by suggesting that it can have a positive impact on a patient's mood, notes the Journal, and it wants the company to distribute "truthful, nonmisleading, and complete corrective messages" about Ultram ER.
Although the video was posted to www.painawareness.org, it has since been removed. The site was launched by Aventine HealthSciences, a medical communications agency, for Pain Awareness Month.
Have you registered with us yet?
Register now to enjoy more articles and free email bulletinsRegister
Already registered?Sign in
Join a growing community of PRWeek comms professionals today
- Read more articles each month
- Sign up for free specialised news bulletins